Overall impact
A (80)

Commentary

Adynxx is a leader for overall positive impact. With an 'A' rating of 80.2 for overall impact (94th percentile compared to all companies), Adynxx ranks 6th out of 30 industry peers, behind Sanofi, Assembly Biosciences, China Pharma and 2 others, and ahead of Alimera Sciences, Kazia Therapeutics, Therapeuticsmd and 21 others. On top material causes for Adynxx's industry (Pharmaceuticals & Biotech), Adynxx performs well in Sustainable Use of Water (95.2 score), Reduced Waste (82.7), Disease Eradication (96.4) and 8 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (39.5 score) and Technology Innovation (25.8).
Impact
Cause ADYX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2007
Employees
6
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
ADYX
Description
Adynxx, Inc. is a clinical stage biopharmaceutical company that focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of the AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain. Additionally, the company is working on AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. Adynxx, Inc. was founded in 2007 and is headquartered in San Francisco, California.
Material causes
Ethos considers the following causes material for Adynxx, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.